leucine rich repeat and fibronectin type III domain containing 3Genealiases: FIGLER1 · SALM4
Q-omics provides the consensus-scored LRFN3 profile across patient tissues and cancer cell-line models. LRFN3 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, LRFN3 is differentially expressed in 12, with the highest sampling consensus in HNSC. Additionally, LRFN3 RNA expression shows 18,969 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight MESO, HNSC, and ACC as cancer lineages where LRFN3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LRFN3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LRFN3 survival associations across molecular data types. LRFN3 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (7) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LRFN3 RNA expression–survival associations across cancer types. High LRFN3 expression shows unfavorable associations in MESO, CESC, LGG and LUAD, but favorable associations in UCS and ESCA. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify MESO as the clearest survival context for LRFN3 RNA expression.
This table summarizes LRFN3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 4. The strongest signals are observed in HNSC for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for LRFN3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LRFN3 shows lower tumor expression in KIRC and higher tumor expression in HNSC, LUAD, LIHC, LUSC and BRCA. The HNSC box plot shows higher LRFN3 RNA expression in tumor versus normal tissue (log2 FC = +0.751, t-test p < 0.001).
This table shows molecular features associated with LRFN3 in patient tissues and cancer cell lines. In patient samples, LRFN3 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, LRFN3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUAD and LARGE_INTESTINE.
